Drug delivery in a tumour cord model: a computational simulation.

The tumour vasculature and microenvironment is complex and heterogeneous, contributing to reduced delivery of cancer drugs to the tumour. We have developed an in silico model of drug transport in a tumour cord to explore the effect of different drug regimes over a 72 h period and how changes in pharmacokinetic parameters affect tumour exposure to the cytotoxic drug doxorubicin. We used the model to describe the radial and axial distribution of drug in the tumour cord as a function of changes in the transport rate across the cell membrane, blood vessel and intercellular permeability, flow rate, and the binding and unbinding ratio of drug within the cancer cells. We explored how changes in these parameters may affect cellular exposure to drug. The model demonstrates the extent to which distance from the supplying vessel influences drug levels and the effect of dosing schedule in relation to saturation of drug-binding sites. It also shows the likely impact on drug distribution of the aberrant vasculature seen within tumours. The model can be adapted for other drugs and extended to include other parameters. The analysis confirms that computational models can play a role in understanding novel cancer therapies to optimize drug administration and delivery.

[1]  Levkovich YuI,et al.  Blood flow velocity in capillaries of brain and muscles and its physiological significance. , 1981, Microvascular research.

[2]  M D'Incalci,et al.  Intratumor Heterogeneity and Its Impact on Drug Distribution and Sensitivity , 2014, Clinical pharmacology and therapeutics.

[3]  J. Double,et al.  A critical appraisal of the predictive value of in vitro chemosensitivity assays. , 1990, Journal of the National Cancer Institute.

[4]  B Hoerni,et al.  Pharmacokinetics of adriamycin in patients with breast cancer: correlation between pharmacokinetic parameters and clinical short-term response. , 1982, European journal of cancer & clinical oncology.

[5]  Lothar Lilge,et al.  The Distribution of the Anticancer Drug Doxorubicin in Relation to Blood Vessels in Solid Tumors , 2005, Clinical Cancer Research.

[6]  S. Piscitelli,et al.  Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer , 1993, Clinical pharmacology and therapeutics.

[7]  Kristian Pietras,et al.  High interstitial fluid pressure — an obstacle in cancer therapy , 2004, Nature Reviews Cancer.

[8]  Spring Berman,et al.  A computational framework for identifying design guidelines to increase the penetration of targeted nanoparticles into tumors. , 2013, Nano today.

[9]  T. Secomb,et al.  A mathematical model for comparison of bolus injection, continuous infusion, and liposomal delivery of doxorubicin to tumor cells. , 2000, Neoplasia.

[10]  S W Smye,et al.  A mathematical model of doxorubicin penetration through multicellular layers. , 2009, Journal of theoretical biology.

[11]  M. Hiraoka,et al.  Diameter of tumor blood vessels is a good parameter to estimate HIF-1-active regions in solid tumors. , 2008, Biochemical and biophysical research communications.

[12]  G. Hortobagyi,et al.  Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma , 1989, Cancer.

[13]  C. Haanen,et al.  Clinical Pharmacokinetics of Doxorubicin , 1988, Clinical pharmacokinetics.

[14]  J. Jenkins,et al.  Plasma pharmacokinetics of adriamycin and adriamycinol: implications for the design of in vitro experiments and treatment protocols. , 1983, Cancer research.

[15]  Ian F Tannock,et al.  Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[16]  L. Mawdesley-Thomas Research into Fish Diseases , 1972, Nature.

[17]  Abdel Kareem Azab,et al.  The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy , 2015, Hypoxia.

[18]  S. Eikenberry Theoretical Biology and Medical Modelling Open Access a Tumor Cord Model for Doxorubicin Delivery and Dose Optimization in Solid Tumors , 2022 .

[19]  Nicolas André,et al.  Computational oncology — mathematical modelling of drug regimens for precision medicine , 2016, Nature Reviews Clinical Oncology.

[20]  Philipp M. Altrock,et al.  The mathematics of cancer: integrating quantitative models , 2015, Nature Reviews Cancer.

[21]  E. Rofstad,et al.  Assessment of microvascular density, extracellular volume fraction, and radiobiological hypoxia in human melanoma xenografts by dynamic contrast‐enhanced MRI , 2007, Journal of magnetic resonance imaging : JMRI.

[22]  T. Waldman,et al.  PTEN Gene Targeting Reveals a Radiation-Induced Size Checkpoint in Human Cancer Cells , 2004, Cancer Research.

[23]  W. Pigram,et al.  Stereochemistry of intercalation: interaction of daunomycin with DNA. , 1972, Nature: New biology.

[24]  E. D. Bal de Kier Joffé,et al.  Autophagy Protects from Trastuzumab-Induced Cytotoxicity in HER2 Overexpressing Breast Tumor Spheroids , 2015, PloS one.

[25]  J. Moore,et al.  Tumour cords in 52 human bronchial and cervical squamous cell carcinomas: inferences for their cellular kinetics and radiobiology. , 1985, British Journal of Cancer.

[26]  Ralph Weissleder,et al.  A Systems Approach for Tumor Pharmacokinetics , 2011, PloS one.

[27]  S. Wallace,et al.  Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. , 1982, Annals of internal medicine.

[28]  B. Desoize,et al.  Cell culture as spheroids: an approach to multicellular resistance. , 1998, Anticancer research.

[29]  Q. Yao,et al.  Overcoming drug resistance in pancreatic cancer , 2011, Expert opinion on therapeutic targets.

[30]  Y. Oda,et al.  Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models , 2014, Cancer science.

[31]  B. Waclaw,et al.  Mutational pathway determines whether drug gradients accelerate evolution of drug-resistant cells. , 2012, Physical review letters.

[32]  Ivanov Kp,et al.  Blood flow velocity in capillaries of brain and muscles and its physiological significance , 1981 .

[33]  T. Secomb,et al.  Two-mechanism peak concentration model for cellular pharmacodynamics of Doxorubicin. , 2005, Neoplasia.

[34]  R M Phillips,et al.  Mathematical and computational models of drug transport in tumours , 2014, Journal of The Royal Society Interface.

[35]  I. Tannock,et al.  Drug penetration in solid tumours , 2006, Nature Reviews Cancer.

[36]  P. Vaupel,et al.  Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. , 2001, Journal of the National Cancer Institute.

[37]  M. Zucchetti,et al.  Bevacizumab-Induced Inhibition of Angiogenesis Promotes a More Homogeneous Intratumoral Distribution of Paclitaxel, Improving the Antitumor Response , 2015, Molecular Cancer Therapeutics.